Skip to main content
. Author manuscript; available in PMC: 2023 Apr 1.
Published in final edited form as: Pharmacogenet Genomics. 2022 Apr 1;32(3):117–124. doi: 10.1097/FPC.0000000000000465

Figure 2.

Figure 2.

The variable chain lengths of (a) unfractionated heparin, (b) enoxaparin, and (c) a pentamer such as fondaparinux offer different pharmacologic profiles, including differences in binding to antithrombin and subsequent inactivation of Thrombin and Factor Xa.